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1. Introduction 
The Papillomaviruses are small double-stranded DNA viruses that infect squamous 
epithelia. They display absolute species-specificity: human papillomavirus (HPV) only 
infect humans, rabbit papillomaviruses only infect rabbits and so forth. They are also 
exquisitely tissue tropic, undergoing a complete infectious cycle only in fully differentiating 
squamous epithelium (Stanley, 2010). Nearly 100 HPVs were described based on the 
isolation of complete genomes (de Villiers et al., 2004). The circular genome, whose size is 
close to 8.0 kilobases (kb), is enclosed in a protein shell made from the major (L1) and minor 
(L2) capsid proteins resulting in virions of approximately 55nm in diameter. It can be 
divided into 3 domains: a noncoding upstream regulatory region (URR), an early region 
with 6 genes (E6, E7, E1, E2, E4 and E5), and a late region encoding two genes (L1 and L2). 
The early genes are involved in DNA replication, transcriptional regulation and cellular 
transformation. The late genes encode capsid proteins and facilitate the entry of viral DNA 
into the cell (Tjalma et al., 2005). Approximately 35 HPV types are known to infect the 
human genital mucosa. They can be grouped as “high risk” (HR) or “low risk” (LR) based 
on their epidemiologic association with cancer. HR types such as HPV16 and HPV18 are 
associated with low and high-grade intraephitelial lesions and invasive cancer. The LR types 
such as HPV6 and HPV11 are associated with genital warts or condyloma acuminate, 
recurrent respiratory papillomatosis, and low-grade cervical intraepithelial lesions (LSIL) 
(Trottier and Franco, 2006). The recognition that infection with HPV is essential for the 
development of cervical cancer led to the development of cervical cancer prevention 
strategies which incorporate HPV testing.  
There are a variety of HPV tests in use worldwide and several of these may be adequate to 
use for cervical cancer screening and HPV vaccination. An ideal assay should have 
(Organization, 2009):  
1. good sensitivity and specificity as evaluated in internal proficiency testing; 
2. ease of transfer to laboratories with varying levels of experience and resources; 
3. affordable cost, to allow use in low-resource settings. 
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It is important that quality assurance programs are established, both in HPV serology and 
DNA typing, in order to evaluate laboratory performance as well as assay characteristics. 
The WHO global reference laboratory recommends proficiency panels composed of a series 
of validated samples, traceable to International Standards, sent to unknown challenges to 
HPV LabNet members. Results allow an evaluation of individual laboratory performances 
and an evaluation of whether assays platforms used by multiple laboratories are robust in 
terms of the generation of acceptable results. HPV cannot be easily propagated by standard 
in vitro culture systems, and in malignant tissue there are little or no infectious HPV 
particles (Organization, 2009). Other classical direct virological diagnosis techniques, such as 
electron microscopy and immunohistochemistry, lack the sensitivity and specificity for the 
routine detection of HPV (Poljak and Kocjan, 2010). For these reasons, the preferred assay 
formats are based on the detection of HPV nucleic acids.  
Molecular methods for HPV DNA detection can be grouped in two main categories: those 
that rely on signal amplification to detect the targets, and those that rely on target 
amplification; most of them are based on polymerase chain reaction (PCR). Results of HPV 
detection are strongly influenced by the technique, and comparison between assays is not 
always possible. This is why all HPV testing steps need careful standardization including 
sample collection, extraction and testing. Stability during transport and storage is very 
important for a good quality DNA. The viral nucleic acid must be preserved to avoid false 
negative results caused by degradation by endogenous endonucleases. To assess the 
integrity of genomic DNA in the specimen and its stability for molecular techniques it is 
crucial to use internal controls such as β-globin. There are several commercially available 
kits (PreservCyt, Cytyc Corp.) for sample transportation that adequately preserve nucleic 
acids for molecular diagnosis even after long periods of ambient temperature storage 
(Molijn et al., 2005, Chan et al., 2006). The choice of which DNA extraction method to use 
depends on the quality of the clinical material and the diagnostic test that will be executed.  
In this chapter, the paramount methods for screening and typing high risk HPV types will 
be described (Table 2). In particular, we describe molecular methods for the identification of 
HPVs based on signal amplified hybridization, polymerase chain reaction (PCR), DNA 
sequencing, type-specific probes, reverse line-blot hybridization, in situ hybridization, 
southern blot hybridization and immunological techniques, including ELISA and western-
blot. In addition, we give examples of commercially available kits, for each assay, and point 
out advantages and limitations of its use.  
2. Signal amplified hybridization assays 
Hybrid Capture to HPV detection was first introduced by Digene Corporation (Gaithesburg, 
MD,USA) in 1995.  This assay is a non radioactive amplification method, based on the 
hybridization of the target HPV-DNA to labeled RNA probes in solution. It captures the 
resulting hybrids detecting them by a specific monoclonal antibody and a chemiluminescent 
substrate, providing a semi-quantitative measurement of HPV-DNA. The second generation 
of hybrid capture assay - hc2 -  uses microtiter plate instead of tubes for the detection of 13 
high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, on liquid-based 
cervical specimens  (Clavel et al., 1999). Specimens containing the target DNA hybridize 
with a specific HPV RNA probe cocktail. The resultant RNA:DNA hybrids are captured 
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onto the surface of a microplate well coated with antibodies specific for RNA:DNA hybrids, 
and detected with a chemiluminiscent substrate. Several alkaline phosphatase molecules are 
conjugated to each antibody. Multiple conjugated antibodies bind to each captured hybrid 
resulting in substantial signal amplification. As the substrate is cleaved by the bound 
alkaline phosphatase, light is emitted being measured as relative light units (RLUs) on a 
luminometer (Figure 1). The intensity of the light emitted denotes the presence or absence of 
target DNA in the specimen. An RLU measurement equal to or greater than the Cutoff 
Value (CO) indicates the presence of high risk HPV DNA sequences in the specimen, 
whereas an RLU measurement lesst han the CO indicates the absence of the specific high 
risk HPV DNA sequences tested or HPV DNA levels below the detection limit of the assay 
(Digene, 2004). This assay has an excellent sensitivity (93% according to referral Kaiser 
Study population) since it can detect HPV16 DNA of a concentration down to 1pg/ml. It is 
considered the most reliable signal amplified hybridization assay and is a CE-IVD test. On 
the other hand, it does not detect all high risk HPV types or very low levels of infection. 
Cross hybridizations with low risk types 6 and 11 may happen (Castle et al., 2002, Seme et 
al., 2006). Despite the negative aspects, it is still the gold standard technique for HPV 
detection, highly recommended for comparative evaluations. The hc2 assay has been used in 
the majority of key randomized controlled and other clinical trials that have proved the 
clinical value of HPV testing (Cox, 2009, Meijer et al., 2009). For this reason it has been 
recommended that new HPV assays should show that they possess similar  characteristics 
as hc2 in the process of clinical validation of the test, before it can be used for cervical cancer 
screening purposes (Meijer et al., 2009).   
 
Fig. 1. Hybrid Capture2 test principle, adapted from 
www.papillomavirus.cz/eng/diagnosis_kits_hybrid.html 
The Cervista™ is another FDA approved qualitative test that detects the DNA from 14 high 
risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The detection of DNA 
from targeted HPV types, with similar characteristics, is performed with three different 
probe mixtures. It uses the Invader® chemistry, a signal amplification method for the 
detection of specific nucleic acid sequences. This method uses two types of isothermal 
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reactions: a primary reaction that occurs on the targeted DNA sequence and a secondary 
reaction that produces a fluorescent signal. In the primary reaction, two types of sequence 
specific oligonucleotides – a probe oligonucleotide and an Invader oligonucleotide – bind to 
the DNA target sequence. When these oligonucleotides overlap by at least one base pair on 
the target sequence, an invasive structure forms that acts as a substrate for the Cleavase® 
enzyme. The enzyme cleaves the 5’ portion (flap) of the probe at the position of the overlap. 
The probes are present in large molar excess and cycle rapidly on and off the target 
sequence so that many cleaved 5’ flaps are generated per target sequence. The cleaved flaps 
then bind to a universal hairpin fluorescence resonance energy transfer (FRET) 
oligonucleotide creating another invasive structure that the Cleavase enzyme recognizes as 
a substrate. The enzyme cleaves the FRET oligonucleotides between the fluorophore and 
quencher and produces a fluorescence signal as the cleaved flaps cycle on and off. For each 
copy of target, the combined primary and secondary reactions result in 106 - 107 fold signal 
amplification per hour. The flap sequences and FRET oligonucleotides are universal since 
they are not complementary to the targeted sequence (Technologies, 2009). Oligonucleotides 
that bind to the human histone 2 gene (HIST2H2BE) are also present in all three 
oligonucleotides mixtures. This serves as an internal control, producing a semi-quantitative 
signal from cellular DNA present in the sample (Day et al., 2009). The Cervista™ HPV 16/18 
uses de same chemistry for the identification of the two most highly oncogenic and 
persistent HPV types. It does not allow the exact determination of HPV type(s) present in 
the clinical specimen, but rather express the result as negative or positive (Day et al., 2009, 
Poljak and Kocjan, 2010). Sensitivity of the Cervista HPV HR test for detection of ≥CIN2 
among women with ASCUS cytology was 92.8% (84.1-96.9) and the negative predictive 
value (NPV) was 99.1% (98.1-99.6). Sensitivity for detection of ≥CIN3 among women with 
ASCUS cytology was 100% (85.1-100) and the NPV was 100% (99.4-100). HPV 16/18 
genotyping test sensitivity of ≥CIN2 was 68.8 (56.6-78.8) and NPV was 96.0% (93.9-97.4). 
HPV 16/18 genotyping test sensitivity of ≥CIN3 was 77.3 (56.6-89.9) and NPV was 99.0% 
(97.7-99.6)(Einsteina et al., 2010). The reproducibility, tested at three different testing centers, 
resulted in an overall inter-run reproducibility agreement of 98.8% [1-sided 95% Confidence 
Lower Limit = 96.9%] and an overall inter-site reproducibility agreement of 98.7% [1-sided 
95% Confidence Lower Limit = 97.9%] (Day et al., 2009). The Cervista HPV HR test showed 
no cross-reactivity with DNA from seven non-oncogenic HPV types or 17 different 
infectious agents at up to 10 copies per reaction (Day et al., 2009). This assay uses standard 
laboratory equipment and instrumentation, such as thermal cyclers and fluorescence plate 
readers reducing the need for additional equipment. It has technology proficiency, due to 
common reaction conditions for all DNA targets, and the simple analysis yields objective 
results producing straightforward interpretation. It should be used in conjunction with 
clinical information derived from other diagnostics and screening tests, physical 
examinations, and full medical history in accordance with appropriate patient management 
procedures (Day et al., 2009). The limitations of Cervista includes: 1) Cervista HPV HR only  
detects 14 high-risk HPV types and the Cervista 16/18 only  detects 2 high risk types; 2) the 
Cervista HPV HR test shows cross-reactivity to two HPV types of unknown risk – HPV 
types 67 and 70 - while the Cervista 16/18 test shows cross-reactivity to high levels of high 
risk HPV 31 (an HPV16 positive result was observed with 107 copies/reaction of HPV31); 3) 
very low levels of infection may cause false negative results; 4) false-negatives can also take 
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place with cervical specimens contaminated with high-levels of contraceptive jelly and/or 
anti-fungal creams, when DNA was isolated with the Genfind™ DNA extraction kit; 5) the 
Cervista HPV HR and 16/18 have been validated only for use with cervical cytology 
specimens collected in Preserv Cyt® solution using a Rovers  Cervex® Brush, Wallach 
Papette® or endocervical Brush/Spatula; 6) performance of Cervista HPV HR and HPV 
16/18 were established exclusively using DNA extracted with the Genfind™ DNA 
extraction kit and using cervical cytology PreserveCyt® specimen processed on the 
ThinPrep 2000 processor; 7) the performance of the Cervista HPV HR and HPV 16/18 test 
has not been established for HPV vaccinated individuals (Technologies, 2009). 
AMPLICOR HPV is a CE-IVD PCR based test launched in 2003, by Roche, in America, and 
in 2004 in Europe. It is capable of detecting 13 HR HPV types with simultaneous assessment 
of the presence of the human β-globin gene as a positive control. It expresses the result of 
the test HR HPV in either negative or positive. The method involves the isolation of nucleic 
acids, PCR amplification, hybridization and absorbance detection. It makes use of a pool of 
PCR primers designed to amplify HPV DNA from 13 high risk genotypes: 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59 and 68. Capture probe sequences are located in polymorphic regions 
of L1 bound by these primers. One additional primer set is used to amplify the human β-
globin gene to provide control for cell adequacy, extraction and amplification. After PCR 
amplification, the HPV amplicon and the β-globin amplicon are hybridized to the 
olinucleotide probles bound to the well of the microwell plate. This hybridization of 
amplicon to the probes increases the overall specificity of the test. Following the 
hybridization reaction the plate is washed to remove unbound material and avidin-
horseradish peroxidase conjugate binds to the biotin-labeled amplicon hybridized to the 
oligonucleotide probes bound to the microwell plate. The absorbance of the reaction mixture 
is measured at 450nm (Monsonego et al., 2005, van Ham et al., 2005). This test has shown 
high analytical sensitivity with an specificity (Poljak et al., 2005) and overall specificity of 
96.5% and sensitivity of 96.1% (Sun et al., 2005). It is comparable to hc2 assay in detecting 
high grade CIN among women examined for abnormal PAP test. This test sensitivity in 
detecting both CIN1 and CIN2-3 is practically identical with the sensitivity of colposcopy 
(with minor abnormality cutoff) but, such as hc2, AMPLICOR assay cannot compete with 
the specificity of cervical (LBC) cytology (Monsonego et al., 2005). The current version of 
Amplicor is not well suited for high throughput testing since it includes many manual steps. 
The recommended extraction of DNA using the AmpliLute liquid media extraction kit is 
especially time-consuming, labor intensive and prone to potential cross-contamination, 
especially when large numbers of samples are being processed. AMPLICOR HPV test does 
not detect HPV 26, 53, 66, 73 and 82, HPV types that have been classified as probably high 
risk types (26, 53, 66) or high risk (73 and 82) types in a large epidemiological study (Munoz 
et al., 2003). Although this test is sensitive, specific, feasible, and easy to handle in routine it 
does not provide specific genotype information.  
A new rapid screening test – careHPV (QIAGEN, Gaithersburg, MD, USA) – based on the 
simplified hc2 technology -  has been developed to detect 14 high-risk types of carcinogenic 
human Papillomavirus: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, in about 2.5 h 
(Qiao et al., 2008). This test is very promising as a primary “screen and treat strategy“due to 
the ability to obtain accurate HPV results in a few hours. This strategy is especially 
important for remote and low resource regions of the world where  follow-up is difficult 
(Qiagen, 2009). The advantages of the use of this test are: 1) it can be run in any setting (no 
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special needs of humidity, temperature, mains electricity or water are required) by a 
healthcare worker with minimum laboratory training; 2) cervical samples can be collected 
by a healthcare worker or can be self-collected by the patient herself; 3) the results are easily 
interpreted and are available in approximately 3 hours (Qiagen, 2009). Limitations include 
the low throughput with only 24-90 specimens processed manually. However, it is very 
promising for developing countries HPV screening strategies such as China (Levin et al., 
2010, Canfell et al., 2011, Shi et al., 2011) and Thailand (Trope et al., 2009). A cross sectional 
study assessed the clinical accuracy of careHPV, comparing it with the hc2, in two county 
hospitals in rural China. A sensitivity and specificity for CIN2+ of 90.0 and 84.2% while 
standard hc2 parameters were 97.1 and 85.6%, respectively (Qiao et al., 2008). 
3. Polymerase chain reaction (PCR) assays 
The polymerase chain reaction (PCR) is a molecular technique capable of amplifying 
selectively a particular DNA sequence several million-fold. It consists of repeated cycles of 
heating and cooling in which a heat stable enzyme (Taq polymerase) uses a denatured 
double strand DNA to synthesize new molecules of DNA. The starting point for DNA 
synthesis are the primers (forward and reverse), short strands of nucleic acid, which 
selectively recognise flanking regions of the DNA template. The sensitivity of this 
methodology is about 10-100 HPV viral genomes in a background of 100ng cellular DNA 
(Zaravinos et al., 2009). The sensitivity and specificity of PCR-based methods vary, 
depending on several aspects such as: DNA extraction procedures, site and type of clinical 
sample, sample transport and storage, primer sets,  size of the PCR product, reaction 
conditions and performance of the DNA polymerase used in the reaction and ability to 
detect multiple types (Garland and Tabrizi, 2006).  
3.1 Type-specific and consensus primer PCR methods 
HPV detection by PCR can be performed using either type-specific primers, which amplify a 
single HPV genotype, or consensus/general primers, which are usually directed to a highly 
conserved region of the L1 gene. Type-specific primers are designed to amplify exclusively a 
single HPV genotype and in order to detect the presence of HPV-DNA in a single sample, 
multiple type-specific PCR reactions must be performed separately (Molijn et al., 2005). The 
use of multiple type-specific PCR reactions has the disadvantages of being labor-intensive, 
costly, time consuming and  requiring the evaluation of the type-specificity of each PCR 
primer set  (Molijn et al., 2005, Zaravinos et al., 2009).  
The use of consensus primers (Table 1) is more convenient because they can amplify a 
broad-spectrum of HPV genotypes. Most laboratories use consensus primers targeting the 
L1 region,  since it is the most conserved part of the genome, referring to the assay as L1 
consensus PCR. Amplification of each of the primer sets will result in different size 
amplicons and consequently can result in a variation in sensitivity for detection of certain 
HPV types, particularly when samples contain multiple genotypes (Garland and Tabrizi, 
2006). There are numerous L1 consensus PCR primers that can be used. The first was 
described in 1989 by Manos and colleagues (Manos et al., 1989). This assay is a set of 
degenerated primers, MY09/MY11, designed with the intent of amplifying in a single 
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reaction all the included genotypes. It generates a 450pb amplicon ready for typing 
determination by subsequent molecular techniques such as restriction fragment length 
polymorphism and DNA sequencing (Manos et al., 1989). At the time that MY09/11 was 
described, only 5 of the 20 or more known HPV genotype sequences had been reported: 
HPV 6, 11, 16, 18, and 33 and the primer set was not entirely homologous even among 
these 5 genotypes. The intertypic sequence variation was compensated by introducing one 
or more degeneracies at the priming sites, resulting in a mixture of 24 unique 
oligonucleotide sequences (Gravitt et al., 2000). The disadvantage of this design is that the 
synthesis of oligonucleotides containing degeneracies is not highly reproducible and 
results in high batch-to-batch variation (Molijn et al., 2005). The degenerate MY09/11 
primers were afterwards replaced by a set of 18 defined primers, PGMY09/11, to improve 
specificity and sensitivity. This amplification system combines a number of distinct 
forward and reverse primers, aimed at the same position of the viral genome. They do not 
contain random degeneracy but may contain inosine, which matches any nucleotide.  
Gravitt (Gravitt et al., 2000) and colleagues grouped the virus types by sequence 
homology in each of the two primer binding regions: a set of 5 upstream oligonucleotides 
comprising the PGMY11 primer pool and a set of 13 downstream oligonucleotides 
comprising the PGMY09 (Gravitt et al., 2000) primer set. Using a defined mixture of non-
degenerate primers has the advantages that the oligonucleotides can be synthesized with 
high reproducibility and PCR is performed at optimal annealing temperatures (Molijn et 
al., 2005). 
Other example of consensus primers is the GP5/6, incorporating one forward and one 
reverse primer aimed at short regions of homology conserved amongst HPV types 1a, 6, 8, 
11, 13, 16, 18, 30, 31, 32 and 33 (Snijders et al., 1990). To improve efficiency, part of these 
sequences were used to elongate GP5 and GP6 at their 3’ ends to generate the primers 
GP5+/6+ (de Roda Husman et al., 1995). The GP5+/6+ primer set generates a 160pb 
amplicon and reveales an improved HPV detection, reflected by a 10 to 100 fold higher 
sensitivity, compared with the GP5/6. The mismatching between the primers and the non 
complementary HPV types (it was only 100% complementary to just a few HPV genotypes) 
is overcome by setting a low annealing temperature at the PCR reaction (Zaravinos et al., 
2009). Qu and colleagues (Qu et al., 1997) compared the MY09/11 and GP5+/6+ primer sets 
in a group of cervicovaginal samples and concluded that despite good agreement in the 
detection of HPV DNA –positive and –negative status, there is a significant difference in the 
detection of multiple types within samples. The MY-PCR primer set was more robust than 
the GP+-PCR method. The second was relatively inefficient in the amplification of HPV 
types 53 and 61 compared with the MY-PCR, which was inefficient in the amplification of 
HPV35.  Chan and colleagues (Chan et al., 2006) compared the 3 methods: PGMY09/11, 
MY09/11, GP5+/6+ in 2006 and concluded that PGMY09/11 showed higher sensitivity with 
a positive rate of 95.8% compared to 84.2% of the MY09/11 and GP5+/6+ methods. 
Regarding samples with multiple infection, PGMY09/11 primer set detected most of them 
(9/11, 81.8%), MY09/11 detected 2/11 (18.2%), whereas GP5+/6+ failed to detect any of 
these. 
General primers in the E1 region have also been described, and several other broad-
spectrum PCR primers were reported, but have not been extensively used in clinical 
situations (Molijn et al., 2005) and therefore will not be mentioned in this chapter. 
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Primer Sequence (5’-3’)a Amplimer 
length (bp) 
Targetb 
MY09/11 (MY09)CGT CCM ARR GGA WAC TGA TC 450 L1 
(MY11)GCM CAG GGW CAT AAY AAT GG 
PGMY09/
11 
(PGMY11)A GCA CAG GGA CAT AAC AAT GG 450 L1 
(PGMY11B)GCG CAG GGC CAC AAT AAT GG 
(PGMY11C )GCA CAG GGA CAT AAT AAT GG 
(PGMY11D)GCC CAG GGC CAC AAC AAT GG 
(PGMY11E)GCT CAG GGT TTA AAC AAT GG 
(PGMY09F)CGT CCC AAA GGA AAC TGA TC 
(PGMY09G)CGA CCT AAA GGA AAC TGA TC 
(PGMY09H)CGT CCA AAA GGA AAC TGA TC 
(PGMY09Ia)G CCA AGG GGA AAC TGA TC 
(PGMY09J)CGT CCC AAA GGA TAC TGA TC 
(PGMY09K)CGT CCA AGG GGA TAC TGA TC 
(PGMY09L)CGA CCT AAA GGG AAT TGA TC 
(PGMY09M)CGA CCT AGT GGA AAT TGA TC 
(PGMY09N)CGA CCA AGG GGA TAT TGA TC 
(PGMY09Pa)G CCC AAC GGA AAC TGA TC 
(PGMY09Q)CGA CCC AAG GGA AAC TGG TC 
(PGMY09R)CGT CCT AAA GGA AAC TGG TC 
(HMB01b) GCG ACC CAA TGC AAA TTG GT 
GP5/6 (GP5)TTT GTT ACT GTG GTA GAT AC 140-150 L1 
(GP6) TGA TTT ACA GTT TAT TTT TC 
GP5+/6+ (GP5+)TTT GTT ACT GTG GTA GAT ACT AC 160 L1 
(GP6+)GAA AAA TAA ACT GTA AAT CAT ATT 
C 
a M, A1C; R, A1G; S, G1C; W, A1T; Y, C1T. 
b L1, HPV late structural protein 1. 
Table 1. Specifications of oligonucleotides used as primers for general HPV detection by 
PCR 
3.2 Polymerase chain reaction-restriction fragment length polymorphisms assays 
(PCR-RFLP) 
PCR-RFLP assay is an alternative technique developed to identify and characterize species 
detecting variations at the DNA sequence level. It involves the digestion of the PCR product 
with specific restriction endonucleases to generate DNA profiles. Appropriate software such 
as Webcutter v2.0 (http://rna.lundberg.gu.se/cutter2/) is used in order to find the most 
suitable restriction site. The restriction enzymes will generate several fragments of variable 
lengths which can be resolved by gel electrophoresis, producing DNA fingerprinting 
patterns (Kado et al., 2001). This method depends on the availability of restriction enzymes 
capable of detecting specific mutations. In addition to several in-house genotyping protocols 
based on PCR-RFLP, there is one commercially available kit. The BIOTYPAP kit (Biotools, 
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Nave, Spain) allows the detection and identification of 31 HPV types: 6, 11, 13, 16, 18, 30-35, 
39, 40, 42-44, 51-54, 56-59, 61, 62, 64 and 66-69, and one subtype (subHPV-44 or subHPV-55). 
The kit consists of a multiplex amplification reaction, using two pairs of primers. One pair of 
primers (Pair1– GEN1 and GEN2) hybridizes with sequences common to all tested HPV 
genotypes (L1 and L2 genes), and therefore, indicates HPV presence. The second pair of 
primers (Pair 2 – ONC1 and ONC2) hybridizes with specific sequences for oncogenic HPV 
genotypes (E6 and E7 genes). The first pair of primers renders a band of approximately 450 
bp, while Pair 2 renders a product of approximately 250 bp. Amplification products are then 
subjected to a restriction fragment analysis, on which different restriction patterns will 
indicate presence of a given HPV genotype (Figure 2) (BIOTYPAP Kit, 2009). Mammas and 
colleagues (Mammas et al., 2010) used the kit for genotyping of HPV in four children with 
respiratory papillomatosis. The use of PCR-RFLP has been shown to be useful in the 
identification of multiple HPV infections as well as the detection of novel HPV types (Kay et 
al., 2002). 
1       2       3       4       5       M 
 
Fig. 2. Detection of HPV with BIOTYPAP Kit. Lane 1 and Lane 3: samples from healthy 
patients; Lane 2: patient infected with a generic HPV; Lane 4: patient infected with an 
oncogenic HPV; Lane 5: negative control; M: 100 bp Ladder, adapted from (BIOTYPAP Kit, 
2009). 
3.3 Polymerase chain reaction-restriction fragment mass polymorphism assay (PCR-
RFMP) 
The PCR-RFMP assay is based on PCR amplification, restriction enzyme digestion, and 
analysis by MALDI-TOF mass spectrometry. The precise sizing of oligonucleotides after 
genotype-specific base variation is detected by fragment scission using type IIS restriction 
enzymes (Lee et al., 2011). The use of a type IIS restriction enzyme makes the RFMP assay 
sequence independent and applicable to a wide variety of HPV genotypes, because these 
enzymes have cleavage sites at a fixed distance from their recognition sites. It is a simple 
and rapid protocol (4-4,5 h) and accurately detects and identifies at least 74 different HPV 
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genotypes (Hong et al., 2008). When Lee (Lee et al., 2011) and colleagues compared the assay 
with the well established automated direct sequencing, the PCR-RFMP had a higher 
analytical sensitivity - 92% and 84% respectively. 
3.4 Real-time polymerase chain reaction based assays (rtq-PCR) 
Real-time PCR reaction, also called quantitative real time PCR, is a technique capable of 
amplifying and simultaneously quantifying the target DNA molecules. At each PCR cycle 
it is possible to measure the amount of amplified product. The detection is performed 
using non-specific fluorescent dyes that intercalate with any double-stranded DNA or 
using sequence-specific DNA probes. The reaction is performed in a Real-time PCR 
thermocycler.  After each cycle, to estimate the DNA concentration, the fluorescence is 
measured with a detector and is compared with a control used as reference. Given its 
capacity to detect the presence and abundance of a specific DNA sequence, rtq-PCR 
techniques have been developed to quantify HPV-DNA in clinical samples. Type-specific 
probes can be combined with fluorescence probes although multiplexing several type-
specific primers within one reaction is technically difficult. Consensus primers are used in 
this technique but are less amenable to quantification than a type-specific system (Molijn 
et al., 2005). This methodology has the following advantages: 1) it is capable of detecting 
the viral load; 2) the reaction can be performed on multiplex, with the use of different 
fluorochromes which emit fluorescence as the PCR reaction proceeds; 3) using a 7-log 
dynamic range to extrapolate viral load/concentration in the standard curve, it is possible 
to detect nucleic acids at very small concentrations which would not be detectable by 
conventional PCR; 4) it is extremely reproducible, rapid and pertinent in a clinical setting 
(Zaravinos et al., 2009). 
Novel RT-PCR methods have been released and are capable of being used as high-
throughput screening tools. The GenoID (GenoID Ltd., Budapest, Hungary) is a molecular 
beacon-based one-step multiplex real-time PCR system which detects 15 high-risk HPV 
types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and 5 low-risk HPV types: 6, 
11, 42, 43 and 44. The optimized PCR reaction mixture contains 16 forward, 16 reverse 
primers and 20 type-specific molecular beacon probes targeted to a special sequence of the 
L1 gene, where a highly variable sequence is flanked by two conserved sequences. 
Molecular beacons detecting high-risk types are 5-FAM-3-DABCYL-labeled, molecular 
beacons for low-risk detection are 5-TET-3-DABCYL-labelled, while the internal control 
added before sample DNA extraction is detected by a 5-FAMTexasRed-3-DABCYL 
wavelength-shifting molecular beacon. Accordingly, fluorescent data for HPV detection are 
collected at 530 nm for high-risk types, 560 nm in case of low-risk types and the reaction 
internal control is detected at 610 nm on a Roche LightCycler 2.0 instrument (Takacs et al., 
2008). The sensitivity for detected types varies between 22 and 700 copies/reaction; the 
assay shows some cross-reactions, however without comprising the overall clinical 
applicability of the system.  
The Abbott Real Time High Risk HPV test (Abbott Molecular Inc., Des Plaines, IL, USA) is 
performed on the m2000rt real-time PCR instrument (Abbott Molecular) and is designed to 
individually genotype HPV16 and HPV18 and detect other 12 HPVs: 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68 using a modified GP5+/6+ primer mix consisting of three forward and 
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two reverse primers. The assay uses four channels for detecting fluorescent probes: one for 
detecting the internal control (human beta-globin), a second one for detecting HPV16, a 
third one for detecting HPV-18, and a fourth one for detecting the remaining 12 hr-HPV 
genotypes. The assay turnaround time is 6 to 8 hours for 96 samples and depends on the 
method used for DNA extraction. The fully automated high throughput m2000sp instrument 
(Abbott Molecular Inc.) or smaller m24sp instrument (Abbott Molecular Inc.) can be used for 
DNA extraction, or alternatively DNA can be prepared manually (Poljak et al., 2009). Halfon 
and colleagues (Halfon et al., 2010b) evaluated the clinical performance of the Abbott Real 
time HR HPV test, in comparison with biopsy, hybrid capture II and Linear Array, for 
detection of high-grade disease (CIN2+) in women with abnormal cytology who referred to 
undergo colposcopic evaluation. All tests had high sensitivity in detecting CIN2+ lesions: 
Abbott RT HR HPV had 90%, LA had 92% and HCII had 95%  and similar specificities: 50%, 
47% and 50% for Abbott RT HR HPV, LA, HCII respectively. The authors concluded that the 
Abbott RT HR HPV assay is good and closely correlated with the other two assays with the 
advantages of automation and ability to identify HPV16 and HPV18. Another study 
compared the performance of Abbott RT HR HPV test with that of Hybrid Capture II in 250 
liquid-based cervical cytology samples diagnosed with ASCUS, collected from Asian 
Screening Population. The two tests showed high concordance (absolute agreement: 90%; 
95% CI = 0.726–0.874). For detecting cases with underlying HSIL/CIN2+, both tests 
achieved 100% sensitivity and 100% NPV but Abbott provided higher specificity (20.83% vs 
12.50%). The RT-PCR assay is found to provide enhanced sensitivity and specificity for 
triage of ASCUS (Wong et al., 2011). This assay is also a reliable, sensitive and specific 
diagnostic tool for the detection and partial genotyping of targeted HPV genotypes in 
formalin-fixation and subsequent paraffin/paraplast embedding cervical cancer tissue 
specimens (Kocjan et al., 2011).  
The cobas 4800 HPV Test (Roche Molecular Diagnostics, Pleasanton, CA, USA) is a real-time 
PCR assay for the detection of 14 high-risk HPV types in a single analysis in patient 
specimens. The test specifically identifies HPV16 and HPV18 while concurrently detecting 
the rest of the high risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The cobas 4800 
System consists of the cobas x 480 instrument for fully automated sample preparation 
directly from primary sample tubes and the cobas z 480 analyser for real-time PCR based 
amplification and detection. The cobas x 480 instrument is an automated multi-channel 
pipetting instrument used to extract, purify, and prepare target nucleic acid for subsequent 
PCR testing on the cobas z 480 analyser. After completion of sample preparation the cobas x 
480 instrument automatically sets up the PCR in a microwell plate. The microwell plate with 
the PCR-ready samples is then manually unloaded, sealed, and transferred to the cobas z 
480 analyser for amplification and detection using real-time PCR (Figure 3) (cobas 4800, 
2010). When Castle and colleagues (Castle et al., 2009) described the cobas 4800 HPV DNA 
Test and compared its performance with the LA test, the percentage of total agreement was 
94.7% (95%CI, 92,5%-96%5%), in 531 tested samples. A study enrolling 47,208 women from 
61 clinical centers across USA (ATHENA study) evaluated the clinical performance of the 
cobas 4800 HPV DNA test. The clinical validation of the assay was achieved by determining 
its performance characteristics for the detection of CIN2+ or worse and CIN3 or worse and 
by comparing with hc2 test. Sensitivy rates for CIN 2 and CIN 3 were 90% (95%CI, 81.5%-
94.8%) and 93,5% (95%CI, 82.5%-97.8%), respectively. The specificity for high grade disease 
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detected by cobas 4800 HPV Test was also comparable with hc2: 70.5% (95%CI, 68.1%-
72.7%) vs 71.1% (95%CI, 68.8%-73.4%), respectively. The main advantage of the assay over 
hc2 is that it provides information on HPV16 and HPV18 separately (Stoler et al., 2011).  
 
Fig. 3. cobas 4800 HPV Test system overview, adapted from (cobas 4800, 2010) 
3.5 Reverse-transcription polymerase chain reaction assays (RT-PCR) 
Although the majority of HPV detection strategies are DNA based, it is possible to look for 
specific HPV viral RNA by incorporating a reverse transcriptase (RT) step before PCR 
amplification (Molijn et al., 2005). Reverse transcriptase is a DNA polymerase enzyme that 
transcribes single-stranded RNA into double-stranded DNA. In RT-PCR a specific mRNA is 
first ‘reverse transcribed’ into its DNA complement (cDNA) and then amplified using 
traditional PCR or rtq-PCR methods. The most relevant transcripts for diagnostic purposes 
are those encoding viral oncoproteins E6 and E7. The detection of viral mRNA can be done 
by reverse transcriptase PCR or by nucleic acid sequence-based amplification (NASBA) 
(Poljak and Kocjan, 2010). 
The Pretect HPV-Proofer (HPV-Proofer; NorChip, Klokkarstua, Norway) is based on real-
time multiplex NASBA and has the advantage of detection type-specific E6/E7 mRNA from 
the carcinogenic HPV types: 16, 18, 31, 33, and 45. Two primer and probe-sets are included 
in each reaction vessel. This assay can therefore be used in monitoring a persistent viral 
infection. Also, it is possible to detect the transforming potential of the infection, due to the 
oncogenic capacity of E6/E7 genes (Molden et al., 2007). The protocol of this assay is based 
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on isothermal RNA amplification, accomplished by the simultaneous enzymatic activity of 
avian myeloblastosis virus (AMV) reverse transcriptase, T7 RNA polymerase, and RNase H. 
For detection, two different types of probes are used, an ECL probe and a molecular beacon 
probe direct against E6/E7 mRNA (Figure 4). As performance control, to avoid false 
negatives due to degradation of nucleic acid,  a primer set and probe directed against the 
human U1 small nuclear ribonucleoprotein-specific A protein (U1A mRNA) is included. Two 
differently labeled molecular beacon probes are used in each multiplex reaction. Fluorescein 
(FAM) is used as a fluorophore for the detection of HPV16, 31 and 33; Texas Red (TxR) is used 
for the detection of U1A, HPV 18 and 45. All the molecular beacons contain the non-
fluorescent quencher Dabsyl CPG (1-dimethoxytrityloxy-3-[O-(N-4’-sulfonyl-4-
(dimethylamino)-azobenzene)-3-aminopropyl]-propyl-2-O-succinoyl-long chain alkylamino- 
CPG) (Kraus et al., 2004, Molden et al., 2007). The performance of HPV-Proofer requires 
standard laboratory equipment, the lambda FL600 fluorescence reader- NASBA platform 
(Bio-Tek, Wnooski, VT, USA) and PreTect Analysis software (NorChip) for analysis of the 
experimental data. The analytical sensitivity of the assay is less than 10 SiHA cells, 
equivalent to 20 copies of HPV16 and less than 1 HeLa cell equivalent to 25 copies of HPV18 
(Lie et al., 2005). All studies that have compared HPV-Proofer with hc2 or different in-house 
or commercial PCR-based HPV DNA assays, showed that HPV-Proofer has a lower clinical 
sensitivity for the detection of CIN2+ lesions than DNA-based assays, but a significantly 
higher clinical specificity (Kraus et al., 2004, Lie et al., 2005, Molden et al., 2007, Szarewski et 
al., 2008).  
 
Fig. 4. Schematic presentation of NASBA including molecular beacon detection, adapted 
from (Molden et al., 2007) 
The NucliSENS EasyQ HPV v1 (NucliSENS; bioMÉRIEUX) is a real-time nucleic acid 
amplification and multiplex detection assay for the qualitative determination of E6/E7 
mRNAs of the HPVs 16, 18, 31, 33 and 45. The assay utilizes the nucleic acid sequence-based 
amplification (NASBA) technology, detecting both viral and bacterial nucleic acids. 
NucliSENS EasyQ HPV version 1 was launched in 2007 and was based on the original 
PreTect Proofer assay, except for the NucliSENS hardware platform and the software for 
NASBA measurements and data analysis (NucliSENS Director software). The latest 
NucliSENS EasyQ HPV assay version 1 has recently been improved in the following ways: 
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taking into account the RNA nature of the HPV-specific targets, the five positive controls for 
the different subtypes and the U1A internal control were changed from single stranded 
DNA to RNA; also, in order to facilitate handling and to increase reproducibility of the 
assay, the positive controls are no longer provided in liquid phase but in freeze-dried 
accuspheres; aiming to improve and harmonize the sensitivity for the five HPV types 
covered by the assay, the concentrations of the primers and beacons for HPV16 and the U1A 
internal control were re-adjusted; the extraction protocol on NucliSENS EasyMAG® system 
was optimized; the HPV assay protocols were updated and the NucliSENtral ™ HPV 
software V1.1 introduced to further improve the convenience of operator use for results 
reporting (Jeantet et al., 2009). The calculated analytical sensitivity ranges from 2.3x102 to 
3.0x104 copies/mL, showing the highest sensitivity for HPV45 and the lowest for HPV31 
(Jeantet et al., 2009). Halfon and colleagues (Halfon et al., 2010a) compared this mRNA assay 
with the hc2 assay in a population of atypical cells of undetermined significance/low-grade 
squamous intraepithelial lesion/high-grade squamous intraepithelial lesion 
(ASCUS/LSIL/HSIL) patients. The clinical sensitivity of NucliSENS EasyQ HPV was 63% 
for the detection of CIN2+ or HSIL, significantly higher than the sensitivity of hc2 and LA 
(49% and 45%, respectively). The sensitivity of the assay is significantly lower than that of 
hc2 and LA (76% vs 95% ans 76% vs 92% respectively).  
The APTIMA HPV Assay (Gen-Probe Incorporated, San Diego, CA) is a multiplex nucleic 
acid test that detects HPV E6/E7 mRNA from 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 and 68. The assay provides a qualitative result (positive/negative) 
for the presence/absence of these high-risk HPV types, but does not determine the specific 
HPV type present in the specimen. The APTIMA HPV Assay involves three main steps, 
which take place in a single tube: capture of the target mRNA using HPV-specific capture 
oligomers and magnetic microparticles; target mRNA amplification using transcription-
mediated amplification, and detect the amplification products (amplicons) using the 
Hybridization Protection Assay (Dockter et al., 2009a). An internal control transcript is 
added to each reaction to verify the performance of each step of the assay: capture, 
amplification and detection. One positive calibrator and one negative calibrator are used to 
determine the validity of the run and to establish the assay cutoff values for the internal 
control and analyse signals. A positive control and a negative control are also processed as 
separate samples and used to determine run validity. The assay can be performed on the 
semi-automated Direct TubeSampling (DTS) systems, or on the fully automated TIGRIS DTS 
system (Gen-Probe Incorporated, San Diego, CA). The throughput is approximately 180 
specimens for 1 operator in about 5 to 6 hours for the DTS systems and approximately 1000 
specimens in about 14 hours for the TIGRIS DTS system (Dockter et al., 2009a). The 
analytical sensitivity of the assay in the semi-automated DTS systems was between 38 and 
488 HPV mRNA copies and in fully automated TIGRIS DTS system was between 17 and 275 
HPV mRNA copies. The overall analytical specificity of the assay was equal to or greater 
than 99% in both systems. Dockter and colleagues (Dockter et al., 2009b) evaluated APTIMA 
HPV Assay performance for detection of high risk HPV and high-grade cervical 
intraepithelial neoplasia (CIN) compared to hc2. The mRNA based assay was found to be 
highly sensitive and specific for the detection of high-risk HPV in clinical samples, with a 
sensitivity of 92% and a specificity of 98%. The results obtained in the DTS and TIGRIS DTS 
systems were equivalent. Another study compared the sensitivity and specificity of several 
tests, including APTIMA HPV Assay, for the detection of high-grade CIN in a population 
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referred to colposcopy because of abnormal cytology (Szarewski et al., 2008). Four adjuvant 
tests had sensitivities greater than 95% for high-grade disease (CIN2+ and CIN3+ 
respectively): Amplicor (98.9% and 99.5%), Hybrid Capture II (99.6% and 99.5%), Linear 
Array (98.2% and 99.0%) and APTIMA (95.2% and 97.4%). Of these, APTIMA showed the 
highest specificity (42.2% and 38.8%). 
4. Sequencing reaction (GP6+) – big dye terminator cycle sequencing kit 
As previously mentioned, sequencing methods of PCR products are also now available for 
high throughput allowing its application to routine clinical analysis (Ekstrom et al., 2011). 
Nested PCR amplification of a conserved region of the HPV L1 gene, with the consensus 
GP5+/GP6+ primers, followed by genotyping with direct DNA sequencing (BigDye 
Terminators, Applied Biosystems) and alignment of the hypervariable region of the L1 gene 
against known HPV genotype sequences, stored in the GenBank database, usually 
determines the genotype of the HPV isolates detected (Molijn et al., 2005). LoTemp™ HiFi® 
DNA polymerase has shown to be 10 times more efficient, than other Taq DNA 
polymerases, in amplifying HPV plasmid DNA by MY09/MY11 PCR and about 100 to 1000 
times more efficient when the first amplification was followed by a GP5+/GP6+ nested PCR 
in tandem (Lee et al., 2007). The nested PCR technology described by Molijn et al. proved to 
be a sensitive method for the detection of 1-10 copies of purified genomic DNA of HPV 
types 16, 18 or 6B. However, 104 - 105 copies of genomic DNA were needed as PCR 
templates for UV visualization of a positive primer amplicon after electrophoresis. 
Reproducibility of this nested PCR assay was confirmed (Molijn et al., 2005).The exploitation 
of this method allows the identification of new HPV types given that it is not intended for 
the identification of specific types. Sequencing protocols, in particular the requirement for 
template purification, are too labor-intensive for routine applications. In the presence of 
samples infected with more than one genotype of HPV are unsuitable for HPV 
determination. Sequences which represent a minority species, in the total of the PCR 
product, may remain undetected underestimating the prevalence of infections with multiple 
HPV genotypes. After detecting a sample with multiple HPV infection the genotype can be 
deduced by two methods: 1) database homology search (BLAST) and 2) phylogenetic 
analyses (Kleter et al., 1999). In any case, it is time consuming and not totally reliable. Thus, 
this method is not readily adapted to routine diagnostic labs. 
5. Type-specific probe assays 
5.1 DNA Microarray genotyping assays 
The DNA microarray system has been largely used in HPV typing (Jacobs et al., 1997). A 
DNA microarray is a collection of microscopic DNA probes attached to a solid surface by a 
covalent bond. Each probe contains picomoles of a specific DNA sequence like a short 
section of a gene. The cDNA targets are fluorescently labelled and under high-stringency 
conditions hybridize with the probes on the surface of a chip. In each spot the fluorescent 
light is detected by excitation with monochromatic light and transformed in image by 
software. This technology can screen a high number of markers per individual and it is 
particularly suited for strategy using large populations. An example of this methodology is 
HPVDNAChip (Biomedlab, Seoul, South Korea) which contains 22 type-specific probes, 
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allowing identification of 15 high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 
69 and 7 low-risk types: 6, 11, 34, 40, 42, 43 and 44. In summary, target HPV DNA is 
amplified by PCR with hpv1/hpv2 primers and labeled utilizing Cy5-dCTP or Cy5-dUTP, 
with primers and conditions described by manufacturer. Secondly, the PCR product is 
hybridized onto the chip and, after washing, the hybridized signals are visualized with a 
DNA chip scanner (Seo et al., 2006). The HPVDNAChip test was successfully implemented 
in a population based study in Korea with 2.470 women (Hwang et al., 2004) and in a study 
that compared the performance of four HPV genotyping assays on a panel of 824 samples; 
the analytical sensitivity of the test was around 80% and specificity for the individual HPV 
types was above 94% (Klug et al., 2008). 
The GG HPVCHIP (GoodGene, Seoul, South Korea) allows the identification of 42 alpha-
HPV types; 15 high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69 and 70; Three 
probable high-risk types: 26, 53 and 66; 20 low-risk types:6, 7, 10, 11, 27, 32, 40, 42, 44, 54, 55, 
57, 61, 62, 72, 73, 91, CP8304/81, and MM7/83, MM8/84; and four undetermined-risk types: 
30, 34, 67 and MM4/82. The DNA chips collect multiple oligonucleotide probes of the 42 
HPV types and human β-globin gene. The DNA is amplified with Cy5-labelled primer for 
E6, E7 and L1 gene and the produced amplicons are applied onto the DNA chip, followed 
by hybridization and the genotypes of HPV within sample are identified by a fluorescent 
scanner (Kim et al., 2006). The performance of the GG DNACHIP was compared with PCR 
sequencing on 100 cervical cancer specimens and both methods detected 98% (98/100) high-
risk types of the samples tested (Kim et al., 2006). 
The HPV GenoArray Test Kit (GenoArray, HybriBio Limited, Hong Kong) uses both DNA 
amplification and Hybrio’s proprietary flowthrough hybridization technique to 
simultaneously identify 21 alpha-HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 42-45, 51-53, 56, 58, 
59, 66, 68 and 81. The test employs a macroarray format with a nylon membrane onto which 
HPV genotype-specific oligonucleotides probes have been immobilized (Grisaru et al., 2008). 
Liu and colleagues (Liu et al., 2010) compared the HPV GenoArray test with Linear Array, 
revealing concordant or compatible results for 97,5% of the samples and discordant results 
for only eight samples (2,5%). The assay appears to be highly sensitive and specific for the 
genotyping of HPV and has the advantage that specifically detects HPV52, which 
overcomes a limitation of the Linear Array. 
Less frequent in peer-reviewed literature are the kits GeneTrack HPV DNA Chip 
(GeneTrack, Genomic Tree, Daejeon, South Korea) and GeneSQUARE HPV Microarray 
(Kurabo Industries, Osaka, Japan). The first identifies 28 HPV types: 6, 11, 16, 18, 31, 33, 35, 
39, 40, 42-45, 51, 52, 54, 56, 58, 59, 62, 66-72 and consists in the amplification of a 450 bp 
region of the L1 gene using MY09/11/HMB01 primers and of an internal control (portion of 
the human interferon-2 gene). To determine the HPV genotype, the amplicons are 
hybridized on a DNA chip with eight microarrays chambers, each containing a duplicate of 
the 28 type-specific probes and a replicate of a human cellular target-specific probe (Oh et 
al., 2004, Poljak and Kocjan, 2010). The GeneSQUARE HPV is a microarray system in 
development that utilizes a multiplex PCR to amplify and identify 23 alpha-HPVs: 6, 11, 16, 
18, 30, 31, 33-35, 39, 40, 42, 45, 51-54, 56, 58, 59, 61, 66 and 68. Type-specific primer pairs are 
used in the assay and the upstream primer in each pair is labeled with biotin at the 5’end. 
After hybridization, the microarray is washed, dried and scanned (Figure 5) (Ermel et al., 
2010, Matsushita et al., 2011). Ermel and colleagues (Ermel et al., 2010) compared the hc2, 
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Linear Array and GeneSQUARE methods and the sample proportion agreement was very 
good, particularly between Linear Array and GeneSQUARE. 
 
Fig. 5. Protocol for HPV-specific probe synthesis by oligonucleotide shuffling used in 
GeneTrack, adapted from (Oh et al., 2004) 
The Infiniti HPV assays (AutoGenomics, Carlsbad, CA, USA) are commercially available 
genotyping platforms for HPV genotyping that uses multiplex PCR, followed by automated 
processing for primer extension, hybridization and detection (Erali et al., 2009). It groups 
three assays: Infiniti HPV Genotyping Assay, Infiniti HPV-HR Quad assay and Infiniti HPV-
Quad Assay. The Infiniti HPV-Quad assay targets the E1 gene of the HPV genome and 
identifies five individual HPV types: 16, 18, 31, 33, and 45, five combinations of HPV types: 
35/68, 39/56, 58/52, 59/51, 6/11 and a β-globin internal control. When Erali and colleagues 
(Erali et al., 2009) compared this assay with Hybrid Capture II, the overall concordance of 
positive and negative results was 83% among the 197 specimens tested.  
The PANArray HPV Genotyping Chip (PANArray, PANAGENE, Daejeon, Korea) uses 
peptide nucleic acid probes for the identification of 31 HPV types: 6, 11, 16, 18, 26, 31-35, 39, 
40, 42-45, 51-54, 56, 58, 59, 62, 66, 68-70, 73, 81, 83 and one subtytpe, subHPV-44 or HPV-55. 
MY09/11 PCR products nested with GP5+/biotinylated-GP6+ primers are used for the 
genotyping (Poljak and Kocjan, 2010). A study comparing the genotyping results of 
PANArray to sequencing with MY09/11 PCR products showed excellent agreement except 
for samples reflecting multiple infections (Choi et al., 2009). 
Another illustration of this methodology is Clart HPV 2 assay (Genomica, Madrid, Spain), 
developed for the detection and genotyping of 35 HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 
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40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89. 
It uses biotinylated primers that amplify a 450bp fragment within L1 region. Co-
amplification of an 892 bp region of the CFTR gene and 1,202 bp fragment of a transformed 
plasmid provides a control to ensure DNA extraction and PCR efficiency (Pista et al., 2011). 
The performance of Clart HPV 2 requires standard laboratory equipment and the Clinical 
Arrays Processor (Genomica) for fully automated microarray processing and genotyping 
analysis (Poljak and Kocjan, 2010). A comparative evaluation of Clart HPV 2 with Hybrid 
Capture 2 Test on samples with cervical intraepithelial neoplasia grade 2 or worse showed a 
clinical sensitivity of 96.9% and specificity of 71.9% (Pista et al., 2011). When Galan-Sanchez 
and colleagues (Galan-Sanchez and Rodriguez-Iglesias, 2009) compared INNO-LIPA HPV 
Genotyping v2, Linear Arrays HPV Genotyping Test and Clart HPV 2 the results were 
absolutely concordant in 31 samples, compatible (some but not all genotypes) in 44 samples 
and discordant in only 3 samples; concluding that all the 3 methods are highly comparable 
and suitable for clinical and epidemiological studies. The advantages of this methodology, 
made a successful use in large-population-based study in Spain, where 2362 women from 
three different regions were investigated (Gomez-Roman et al., 2009). 
The PapilloCheck HPV-Screening Test (Greiner Bio-One GmbH, Frickenhausen, 
Germany) is one of the two most frequently used PCR-microarrays-based assays (Poljak 
and Kocjan, 2010). It is a PCR-based test using a consensus primer set targeting the E1 
HPV gene. HPV oligoprobes immobilized on a DNA chip allow for the identification of 24 
HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42-45, 51-53, 56, 58, 59, 66, 68, 70, 73 and 82. Each 
PapilloCheck chip contains 12 wells defined by elevated rims, each of which contains one 
PapilloCheck array with 28 probes, each in 5 replicate spots (Dalstein et al., 2009). This 
test utilizes the amplification of 350 pb HPV DNA fragment as a new consensus primer 
set: each reverse primer was extended at 5’ end with a universal tag. Additionally, a 
region within the human ADAT1 gene is simultaneously amplified using fluorescent-
labeled primers with Cy5-dUTP. The amplicons hybridize to HPV specific oligoprobes 
immobilized on the DNA chip the readings are performed on a CheckScanner instrument 
(Dalstein et al., 2009). Several comparative evaluations of PapilloCheck with other HPV 
assays have been published (Halfon et al., 2010c, Hesselink et al., 2010, Iftner et al., 2010, 
Schopp et al., 2010, Kitchener et al., 2011). This genotyping test was compared with 
SPF10PCRLiPav and PGMY09/11 on Hybrid Capture2 pretested samples (Schopp et al., 
2010). From results of 826 cervical samples, the PapilloCheck found 100% sensitivity in 
HPV types 53, 56 and 33. The lowest detection rate was observed for type 35 (72,2%) and 
the detection rates for the identification of high-grade intraephitelial neoplasia (CIN2+) 
ranged from 93,7% (PGMY09/11 PCR) to 98,4% (PapilloCheck, SPF10 PCR, HC2), leading 
to the conclusion that the  PapilloCheck gives comparable results on established PCR 
methods (Schopp et al., 2010). Halfon and colleagues (Halfon et al., 2010c) compared 
PapilloCheck, Linear Array and hc2 in 239 women referred for colposcopy and histology, 
concluding that all tests showed a good sensitivity (greater than 90%) without statistically 
relevant differences between them.  
The application of microarray technology as a diagnostic toll shows great advantages, 
since microarray can discriminate HPV genotypes and identify multiple infections (Kim et 
al., 2003). Ideally, a larger number of HPV type-specific probes could be spotted on a chip, 
augmenting the quantity of HPVs genotyped by assay. Unfortunately this method 
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requires the presence of expensive equipment and therefore is not suitable for all the 
laboratories.  
5.2 Suspension array genotyping assays (HPV-SA) 
The HPV-SA provides a rapid and cost-effective method to simultaneously detect 
different HPV genotypes. This technology uses microspheres as array elements that carry 
appropriate receptor molecules such as DNA oligonucleotide probes, antibodies, or other 
proteins. Microspheres are readily suspendable in solution and possess distinct optical 
properties. Each bead can easily be differentiated based on variations and intensity of 
colour. The most common detection systems are light scatter or fluorescence from an 
internal dye. The Luminex xMAP system is a flexible analyzer based on the principle of 
flow cytometry. It incorporates a proprietary process to internally dye polystyrene beads 
with two spectrally distinct fluorochromes. Each bead set is usually coupled to a single 
oligonucleotide probe specific for one HPV type. Genotyping is done by reverse 
hybridization using biotinylated PCR amplicons. After denaturing and hybridization of 
target HPV sequences to the bead-bound probes, labeling of the hybridized biotinylated 
amplicons is done using R-phycoerythrin-labelled streptavidin, serving as a reporter 
fluorophore. The bead sets are then read and analysed on a Luminex analyser (Poljak and 
Kocjan, 2010).  
There are several in-house genotyping protocols based on xMAP technology. Jiang and 
colleagues (Jiang et al., 2006) developed a rapid high-throughput DNA suspension assay, 
capable of simultaneously typing 26 HPVs: 6, 11, 16, 18, 26, 31, 33-35, 39, 40, 42-45, 51-54, 
56, 58, 59, 66, 68, 73 and 82. The HPV-SA consists of 26 different microsphere sets with 
spectral addresses. Each microsphere set shows an HPV type-specific probe on its surface, 
and they can be combined allowing up to 26 different HPV targets to be measured 
simultaneously in a single reaction vessel (Figure 6). Another in-house SA protocol was 
developed by Oh and colleagues (Oh et al., 2007) combining PCR amplification with 
Luminex hybridization. The use of HPV type-specific probes and YBT L1/GP6-1 primers 
detects HPVs 6, 16, 18, 31, 35, 42, 51, 52, 55, 56, 58, 59, 66, 67 and 68. The authors compared 
the SA to the established HPV DNA microarray chip for PCR products derived from 53 
clinical samples. The evaluation showed excellent agreement as the SA was a very 
sensitive and reproducible technique for simultaneously genotyping of all clinically 
relevant genital HPV types (Oh et al., 2007). 
In addition, at least two commercial assays based on this technology are available at present. 
The Multiplex HPV Genotyping kit v1.0 (Progen/Multimetrix, Heidelberg, Germany) is a 
research use only (RUO) assay that allows detection and identification of 24 HPV types: 6, 
11, 16, 18, 26, 31, 33, 35, 39, 42-45, 51-53, 56, 58, 59, 66, 68, 70, 73 and 82. The sample is 
subjected to PCR amplification, using sets of biotinylated primers contained in the kit.  The 
amplicons are added to bead mix, containing 26 distinct bead populations coupled to 24 
HPV, one β-globin and one hybridization control specific oligonucleotide probe. The β-
globin control serves as quality control for genomic DNA in the PCR. After thermal 
denaturing and hybridization of target sequences to the bead-bound probes, labeling of the 
hybridized biotinylated PCR products is achieved by R-phycoerythrin labeled streptavidin. 
Schmitt and colleagues (Schmitt et al., 2006) compared the performance of Multiplex Human 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
222 
Papillomavirus Genotyping assay to an estabilished reverse line blot assay on GP5+/6+ PCR 
products derived from 94 clinical samples. The evaluation showed an excellent agreement 
but also a higher sensitivity of the Multiplex assay.  
 
Fig. 6. Schematic representation of the HPV-SA. After HPV DNA extraction  (A), the 
template was amplified with the MY09/11 primer set (B). PCR products are transferred to a 
PCR tube containing the 26-plex HPV-SA and hybridized (C). After washing, the hybridized 
microspheres were incubated with streptavidin-R-phycoerythrin at room temperature for 30 
min (D). Finally, the mixture is analysed on the Luminex100 analyser (E), adapted from 
(Jiang et al., 2006). 
The digene HPV genotyping LQ Test RUO (Digene LQ Test; Qiagen) uses multiplex, bead-
based xMAP technology and an automated, high-throughput read-out by either the 
LiquidChip 200 workstation (Qiagen, Hilden, Germany) or Luminex 100 IS System 
(Luminex Corporation, Austin, TX, USA). The test was developed for identification of 18 
high-risk HPVs: 16, 18, 26, 31, 33, 35, 39, 45, 51-53, 56, 58, 59, 66, 68, 73 and 82 using 
GP5+/6+ PCR products. Read-out of this assay is expressed as the medium fluorescent 
intensity of the reporter fluorescence for each genotype (Geraets et al., 2009b). When 
compared with in-house GP5+/6+, the assay demonstrated high agreement for overall 
detection and type-specific identification (Geraets et al., 2009b).  
6. Reverse line-blot hybridization-based HPV genotyping assays 
It is the most common method used for HPV genotyping nowadays. In these types of assays 
a fragment of the HPV genome is first amplified by PCR, using biotinylated HPV-specific 
primers, and the resulting amplicons are then denatured and hybridized with HPV-specific 
oligonucleotide probes immobilized as parallel lines on nylon or a nitrocellulose membrane 
strip. After hybridization, streptavidin-conjugated alkaline phosphatase or horseradish 
peroxidase is added, which binds to any biotinilated hybrid formerly produced (Figure 7). 
Incubation with chromogenic substrates yields a colored precipitate at the probe positions 
where hybridization occurs. The genotyping strip is then visually interpreted by comparison 
with the test reference guide for each of the targeted HPV types. The principle of INNO-
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LiPA HPV Genotyping assay is based on the amplification of a 65bp region of the HPV L1 
gene, using biotinylated SPF10 primers, followed by the hybridization of the resulting 
amplicons with HPV specific oligonucleotide probes immobilized on a nitrocellulose strip. 
This is one of the most widely used HPV genotyping kits and there are several versions 
developed of which the first version, the INNO-LiPA25 HPV genotyping V1.0 (Labo 
Biomedical Products, Rijswick, The Netherlands) allowed the identification of 26 HPVs: 6, 
11, 16, 18, 31, 33, 34, 35, 39, 40, 42,43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73 and 74 
(Kleter et al., 1999). More recent versions of this assay, the INNO-LiPA HPV Genotyping v2 
and INNO-LiPA HPV Genotyping CE Assays (Innogenetics) allowed the identification of 24 
and 17 individual types, respectively. The latest version, INNO-LiPA HPV Genotyping 
Extra, allows the simultaneous identification of 28 different HPV types: 6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69/71, 70, 73, 74 and 82. The former 
assay contains an additional primer pair, in the amplification mix, for the amplification of 
the HLA-DPB1 gene to check for PCR inhibition, sample quality and DNA extraction, as well 
as an anticontamination system based on uracil-N-glycosylase (Poljak and Kocjan, 2010). 
Several evaluation studies have been performed in recent years. A recent study compared 
real-time multiplex HPV PCR assays with INNO-LiPA Genotyping Extra suggesting 
increased sensitivity of DNA HPV detection by type-specific multiplex HPV PCR assays 
(Else et al., 2011). Another interesting and important assessment was the comparative 
evaluation of different extraction methods for genotyping with INNO-LiPA and Linear 
array genotyping tests. This study suggests that the use of consistent protocols for DNA 
purification is a priority to guarantee intra-assay reproducibility over time (Dona et al., 
2011). INNO-LiPA HPV Genotyping Extra is also recommended for the use with paraffin-
embedded tissue. After comparison with Linear Array HPV Genotyping Test the INNO-
LiPA genotyping Extra revealed greater sensitivity for HPV genotyping from archival tissue 
(Tan et al., 2010). INNO-LiPA Extra has a sensitivity of 20-70 viral copies per assay 
(estimated for HPV-16, 18, 31, 45 and 52) (Seme et al., 2009). 
 
Fig. 7. INNO-LiPA HPV Genotyping test principle, adapted from INNO-LiPA brochure. 
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As with INNO-LiPA, Linear Array HPV Genotyping assay is based on the amplification of a 
region of the HPV L1 gene (450 bp). This genotyping test also amplifies a 268bp region of the 
human β-globin gene, using biotinylated primer sets PGM09/PGMY11 and PC04/GH20, 
respectively. Subsequent hybridization of the resulting amplicons is made onto a single-
typing nylon strip coated with HPV type specific and β-globin specific oligonucleotide 
probes. This test is one of the most commonly used HPV genotyping assays which combines 
PCR amplification and reverse line-blot hybridization for the identification of 36 HPV types: 
6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 
70, 71, 72, 73, 81, 82, 83, 84 and 89 and one subtype (subHPV-82 or IS39) (Poljak and Kocjan, 
2010). It is registered for use in the European Union (CE-IVD) but not available for use in the 
United States. Numerous comparative evaluations of Linear Array with other HPV 
genotyping assays have been performed. All studies reported high concordance amongst 
hybridization genotyping methods and suitability for clinical and epidemiological studies 
(Galan-Sanchez and Rodriguez-Iglesias, 2009). Linear Array has revealed good correlation 
and perfect agreement with hc2, with high sensitivity; 100% detection of cervical 
intraepithelial neoplasia (CIN) III was shown by both Linear array and hc2 (Paolini et al., 
2011). Comparison of this genotyping assay with real-time multiplex HPV PCR assays, 
holding as constant the DNA extraction method (Qiagen Spin blood kit), revealed that 
multiplex PCR assays detect more HPV-positive specimens for the 14 HPV types common to 
both than Linear Array HPV genotyping assay. Type-specific agreements between the 
assays were good but were often driven by negative agreement in HPV types with low 
prevalence, as evidenced by reduced proportions of positive agreement. An alternate DNA 
extraction technique (Qiagen MinElute kit) impacted subsequent HPV detection in both the 
multiplex PCR and Linear Array (Roberts et al., 2011). A comparative evaluation with 
INNO-LiPA has shown high concordance amongst both methods; however, when 
comparing individual HPV types, Linear Array was able to detect significantly more HPV-
16, 18, 39, 40, 42, 54, 58, 59, 66, 70 and 68/73, and fewer HPV-11, 31 and 52 than INNO-LiPA 
(Castle et al., 2008). Furthermore, INNO-LiPA was able to detect more multiple HPV 
infections and a greater number of HPV types per multiple infection (Castle et al., 2008). 
Linear array has shown a sensitivity of 98.2% and a specificity of 32.8% for the detection of 
CIN II+ lesions (Szarewski et al., 2008). 
The Digene HPV Genotyping RH Test RUO is a reverse line-blot assay designed for the 
detection and identification of 18 HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 
66, 68, 73 and 82. As the previous genotyping tests it is based on the PCR amplification of a 
150bp region of the HPV L1 gene using biotinylated GP5+ and GP6+ primers, followed by 
the hybridization of the resulting amplicons onto a single-typing nitrocellulose strip 
containing 18 HPV type-specific probe lines (Geraets et al., 2009a). Digene HPV genotyping 
RH Test RUO was compared to INNO-LiPA genotyping test Extra showing comparable 
genotyping results. However, INNO-LiPA identified significantly more samples with 
multiple HPV types (Seme et al., 2009). Another evaluation study compared the Digene 
genotyping RH test with the in-house Reverse Line Blot (RLB) genotyping assay. Both 
genotyping assays demonstrated high concordance, in 493 HC2-positive samples, for overall 
HR HPV detection and type-specific identification of the 18 HR types. The Digene RH Test 
revealed positivity for one or more HR HPV type(s) in 86.6% of the HC2-positive women, 
and negativity was confirmed in 97.9% of the HC2-negative women. The Digene HPV 
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Genotyping RH Test revealed a high genotyping agreement with the established RLB assay 
on GP5+/6+ amplimers (Geraets et al., 2009a). It was reported recently another study 
encompassing the Digene HPV Genotyping RH test. The objective was to test whether the 
RH Test and LQ Test (XMap based) can be used as an universal hrHPV genotyping test. 
Self-collected 416 cervico-vaginal specimens from an epidemiologic study were analyzed 
with Amplicor. The amplimers obtained were also tested with the RH Test and LQ Test for 
identification of 18 HPV types, including the 13 hrHPVs targeted by Amplicor. 197 
specimens were positive by Amplicor, in which the RH Test and LQ Test identified one of 
the 13 hrHPVs in 94.4% and 98.0%, respectively. In 219 specimens remaining negative by 
Amplicor, the RH Test and LQ Test, performed on the Amplicor amplification products, still 
detected one of the 13 hrHPVs in 3.7% and 5.5% respectively, and include identification of 
HPV53, 66, and 82. Overall, the RH and LQ Tests demonstrated high concordance with 
Amplicor for hrHPV detection (κ=0.908 and κ=0.923, respectively). The authors suggest that 
the digene HPV Genotyping RH and LQ Tests can be directly used for amplimers generated 
by the Amplicor HPV Test (Geraets et al., 2011). The latest version of Digene RH test (v1.0) 
includes an additional primer pair for human β-globin gene amplification, serving as an 
internal control for PCR inhibition and adequate sample taking and DNA purification 
(Poljak and Kocjan, 2010). 
The EasyChip HPB Blot kit (HPV Blot kit; King Car, Taiwan) is a reverse dot-blot assay 
designed for the identification, in the latest version, of 39 types of HPV: 6, 11, 16, 18, 26, 31, 
32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 72, 74, 82, 
CP8061, CP8304, L1AE5, MM4, MM7 and MM8. The biotinylated PCR amplicons of several 
HPV general primer sets or their combinations can be used for genotyping, including 
MY11/MY09, PGMY11/PGMY09, GP5+/GP6+, MY11/GP6+, MY11/GP6+ nested with 
GP5+/GP6+ and SPF1/GP6+. The latest version of this kit provides two standardized PCR 
amplification mixes: in the first, a modificed MY11/GP6+ primers set is used to amplify a 
190bp region of the HPV L1 gene; in the second, the quality of extracted DNA is validated 
by amplification of a 136bp region of the human GAPDH gene. The resulting amplicons 
from an individual DNA sample are genotyped together on a single-typing nylon 
membrane containing the 39 HPV type-specific and one GAPDH-specific oligonucleotide 
probe marked in duplicate (Poljak and Kocjan, 2010). The evaluation of the sensitivity, 
specificity, reliability and reproducibility of the EasyChip HPV blot for HPV genotyping 
was performed in two studies. In the first, type-specific sensitivity and specificity for the 39 
types of HPV were examined. The operating environment, reliability, reproducibility and 
blot interpretation were assessed by a quality assurance system. Each batch experiment 
contained samples from 89 cervical specimens and 7 extrinsic controls. Caski, HeLa and 
Jurkat cells, male human blood cell DNA and sterile water were used to assess reliability. 
Furthermore, pairs of sibling controls were used to assess reproducibility. The overall 
sensitivity of HPV detection was 1-50 copies of HPV genome equivalent. There was no 
cross-reactivity with amplicons of other HPV genotypes. One hundred batch experiments 
demonstrated that the reliability was excellent. The intra-batch and inter-batch 
reproducibility was 98 and 97%, respectively. The authors concluded that the EasyChip 
HPV blot is a highly sensitive, reliable and reproducible tool for detection and identification 
of HPV genotypes (Lin et al., 2007). The second study compared the efficacy of HPV 
detection and typing with a general PCR-based genotyping array with EasyChip HPV Blot. 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
226 
The concordance of the two tests in determining HPV positivity was 96.8% (419/433), with a 
Cohen's kappa=0.93 (95% CI: 0.90-0.97) and McNemar's test of P=1.0, which indicates 
excellent agreement. The overall concordance of the two tests in the identification of type-
specific HPV was 91.0%. Sensitivity (90-100%), specificity (99.2-100%), and accuracy (98.6-
100%) rates of HPV Blot against the gold standard were satisfactory for HPV-16, 18, 58, 33, 
52, 39, 45, 31, 51, 70 while HPV-71 (63.6%) had suboptimal sensitivity. The authors conclude 
that the modified MY11/GP6+ PCR-based HPV Blot assay is accurate and sensitive for 
detection and genotyping of HPV in cervical swab samples (Lin et al., 2008). 
M&D REBA HPV-ID® is a molecular diagnostic kit for genotyping HPV; it  detects 15 high-
risk genotypes:16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 53, 66 and 10 low-risk genotypes: 
6, 11, 42, 43, 44, 70, 72, 81, 84, 87 , simultaneously. Genetic target of REBA HPV-ID® is the 
HPV L1 gene, which is expressed at the late stage of infection cycles in the host cells. The kit 
is based on one-step nested PCR with biotinylated MY09/11 and GP5+/6+ primers and 
subsequent genotyping of the resulting amplicons with a single typing strip containing 23 
HPV type-specific probes and one HPVV universal probe. There are no evaluation studies 
about this kit in peer-reviewed literature (Inc, M&D, Poljak and Kocjan, 2010).  
The reverse hybridization methodology uses standard laboratory equipment and the 
methodology is both reproducible and rapid. The price per sample can limit its use.  
7. In situ hybridization assays (ISH) 
In situ hybridization allows the detection of intact viral DNA directly in tissues sections or 
cell preparations (in situ). The method is based on the recognition and following bond of the 
labelled probe with the complementary viral target.  The sample is fixed in fixative solution 
in order to preserve the tissue morphology and to prevent loss of genetic material (Carlson 
and Hu). The result of the hybridization reaction is evaluated microscopically and the 
appearance of a specific precipitate is indicative of infection (Huang et al., 1998, Poljak and 
Kocjan, 2010). Generally the assay is based on four steps: tissue fixation, permeabilization of 
tissue samples, hybridization of the sample with probes, and detection of the HPV positive 
cells. Critical points for a successful ISH test are the hybridization and post-hybridization 
treatment. Hybridization is performed by incubating the fixed tissue with the solution 
containing the hybridization probe and washing the tissue to remove the unbound probes. 
During these steps, many parameters play a crucial role. Different lengths of probes and 
different labelling conditions are an example (Montgomery, 2002). The ISH probe cocktails 
available in the market for HPV detection are several.  The latest generation probes utilize 
stacked antibodies to enhance the sensitivities and probes containing viral genomic DNA in 
double strand form (INFORM HPV III test). The target of the probes can be the viral DNA 
and mRNA sequences or viral mRNA transcript in human cells. ISH assay showed a low 
sensitivity (50%) but a significantly higher specificity (Caussy et al., 1988). The values can 
vary, depending on the commercially method utilized.  
INFORM HPV III test (Ventana, Tucson, AZ, USA) represents the last generation 
commercial kit for detecting HPV DNA in cytological and histological specimens. It utilizes 
stacked antibodies to enhance the sensitivity of the technique (Poljak and Kocjan, 2010). The 
antibody stacks consist of a primary antibody that binds the dinitro-phenol hapten linked to 
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the probe, a secondary antibody, a biotinylated tertiary antibody, and a streptavidin–
alkaline phosphatase conjugate that generate the final colour precipitates. Several are the 
probe cocktails available for low and high HPV risk detection. The probe B and C target 12 
HPVs: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66. 
GenPoint HPV Biotinylated DNA probe is the last generation ISH kit using the GenPoint 
Tyramide Signal Amplification System (Dako) (Glostrup, Denmark). It can be used in both 
cytological and histological specimens. The probe is biotin-labeled and consists of a viral 
genomic double-stranded DNA of 500 bp (Gebeyehu et al., 1987). Biotin can be detected by 
using enzyme conjugates of streptavidin to produce covalent bounds with tyramide 
substrates and chromogenic indicator dye diaminobenzidine (DAB) (Bobrow et al., 1989). 
DAB is oxidized by peroxidase enzymes to produce a dark brown precipitate that can be 
visualized on Dako Hybridizer and Autostainer Plus (Poljak and Kocjan, 2010). The probe 
cocktail recognises 13 HPVs: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. In a 
comparative study of INFORM III, GenPoint, and HPV PCR evaluated on 58 tissue 
specimens, GenPoint showed the same specificity (100%) then INFORM III but lower 
sensitivity (Kong et al., 2007).  
ZytoFast HPV Probes (ZytoVision, Bremerhaven, Germany) are specific probes for the 
detection of viral DNA and mRNA of E6, E7, and L1 proteins. It can be used in both 
cytological and histological specimens. The probes are biotin or digoxigenin labelled and 
consist of HPV-type-specific oligonucleotides (Poljak and Kocjan, 2010).  The target is 
indirectly detected using an antidigoxigenin or antibiotin enzyme conjugated antibody. The 
use of a chromogenic substrate leads to the formation of a colour precipitate that is 
visualised by light microscopy. The ZytoFast HPV Kit is designed for the detection of low 
risk HPV types 6 and 11 and high risk types 16, 18, 31, and 33.  
HPV OncoTect Test Kit (OncoTect; IncellDx, El Camino Real Menlo Park, CA, USA; Invirion 
Diagnostics, Oak Brook, IL, USA) measures the number of transforming cells and the 
quantity of E6, E7 mRNA in each intact human cell. The kit works as indicator of disease 
activity. The percentage of tested cells that overexpress the viral mRNAs provides a specific 
indication about the risk of an HPV infection can turn into cervical cancer (IncellDx, 
2010)(IncellDx, 2010)(IncellDx, 2010)(IncellDx, 2010)(IncellDx, 2010, Bhat et al., 2007). 
Generally, HPV OncoTect Test is used in parallel with other HPV protocols (Poljak and 
Kocjan, 2010). The sensitivity and the specificity of the test are high (83.3% and 91.3% 
respectively) and is significantly increased (Narimatsu and Patterson, 2005). It is possible to 
detect 95% of infected cells in moderate dysplasia (HPV OncoTect™, 2010, Liu et al., 2007). 
The advantages and disadvantages of this technique depends on the methodologies and the 
kind of probe used (Feldman et al., 1997): double stranded DNA probes are easy to use but 
need reannealing during the hybridization (decreasing the probe availability); single 
stranded DNA probes does not need probe denaturation and no reannealing during 
hybridization but it is technically complex. RNA probes have high specific activity, no probe 
denaturation needed, no reannealing, but less tissue penetration.  Finally, oligonucleotide 
probes have stable good tissue penetration (small size), no self-hybridization, but lower 
specific activity, so less sensitive, less stable hybrids, and access to DNA synthesizer needed. 
The ISH based tests for HPV detection are insufficiently clinically validated. They are not 
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used in routine screening  because the methodology is too laborious and not sufficiently 
sensible (Poljak and Kocjan, 2010). 
 
Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
hc2 Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
 - 93%  
Cervista™ Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
-  92,8%  
Amplicor Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
- 96,1% 96,5% 
careHPV Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
- 90,0% 84,2% 
GenoID rtq-PCR DNA HPVs16, 18, 26, 
31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 
66, 68, 6, 11, 42, 
43 and 44. 
-   
Abbott 
Real Time 
HR HPV 
test 
rtq-PCR DNA HPVs31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66 and 68.
HPV16 and 
HPV18. 
90,0% 50% 
Cobas4800 rtq-PCR DNA HPVs31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66 and 68.
HPV16 and 
HPV18. 
90,0% 70,5% 
Pretect 
HPV-
Proofer 
RT-PCR mRNA HPVs16, 18, 31, 
33 and 45. 
- 78,1% 75,5% 
NucliSENS 
EasyQ 
HPV v1 
RT-PCR mRNA HPVs16, 18, 31, 
33 and 45. 
- 63%  
APTIMA 
HPV Assay 
RT-PCR mRNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
- 92% 98% 
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Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
HPVDNA 
chip 
DNA 
Microarray
DNA - HPVs16, 
18, 31, 33, 
35, 39, 45, 
51, 52, 56, 
58, 59, 66, 
68, 69, 6, 11, 
34, 40, 42, 
43 and 44.
80% 94% 
GG 
HPVCHIP 
DNA 
Microarray
DNA - HPVs16, 
18, 31, 33, 
35, 39, 45, 
51, 52, 56, 
58, 59, 68, 
69, 70, 26, 
53, 66, 6, 7, 
10, 11, 27, 
32, 40, 42, 
44, 54, 55, 
57, 61, 62, 
72, 73, 91, 
CP8304/81, 
MM7/83, 
MM8/84, 
30, 34, 67 
and 
MM4/82. 
 
HPV 
GenoArray 
Test Kit 
DNA 
Microarray
DNA HPVs6, 11, 
16, 18, 31, 
33, 35, 39, 
42-45, 51-
53, 56, 58, 
59, 66, 68 
and 81.
 
GeneTrack 
HPV DNA 
Chip 
DNA 
Microarray
DNA HPVs6, 11, 
16, 18, 31, 
33, 35, 39, 
40, 42-45, 
51, 52, 54, 
56, 58, 59, 
62 and 66-
72. 
 
Clart HPV2 DNA 
Microarray
DNA - HPVs6, 11, 
16, 18, 26, 
96,9% 71,9% 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
230 
Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
31, 33, 35, 
39, 40, 42, 
43, 44, 45, 
51, 52, 53, 
54, 56, 58, 
59, 61, 62, 
66, 68, 70, 
71, 72, 73, 
81, 82, 83, 
84, 85 and 
89. 
Multiplex 
HPV 
genotyping 
kit v1.0 
Suspension 
array 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 42-45, 
51-53, 56, 
58, 59, 66, 
68, 70, 73 
and 82. 
  
digene 
HPV 
genotyping 
LQ Test  
Suspension 
array 
DNA - HPVs16, 
18, 26, 31, 
33, 35, 39, 
45, 51-53, 
56, 58, 59, 
66, 68, 73 
and 82. 
  
INNO-
LiPA v2 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 40, 43, 
44, 45, 51, 
52, 53, 54, 
56, 58, 59, 
66, 68, 
69/71, 70, 
73, 74 and 
82.  
  
Linear 
Array HPV 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 40, 42, 
44, 45, 51, 
98,2% 32,8% 
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Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
52, 53, 54, 
56, 58, 59, 
61, 62, 64, 
66, 67, 68, 
69, 70, 71, 
72, 73, 81, 
82, 83, 84 
and 89. 
Digene 
HPV 
Genotypin
g 
Reverse 
line-blot 
DNA - HPVs16, 
18, 26, 31, 
33, 35, 39, 
45, 51, 52, 
53, 56, 58, 
59, 66, 68, 
73 and 82. 
  
EasyChip 
HPB Blot 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 32, 33, 
35, 37, 39, 
42, 43, 44, 
45, 51, 52, 
53, 54, 55, 
56, 58, 59, 
61, 62, 66, 
67, 68, 69, 
70, 72, 74, 
82, CP8061, 
CP8304, 
L1AE5, 
MM4, 
MM7 and 
MM8.  
90,0% 99,2% 
INFORM 
HPV III 
In situ
hybridizati
on 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58 and 66.
- ~50%  
GenPoint 
HPV 
Biotinylate
d DNA 
In situ
hybridizati
on 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
- - 100% 
 
 
Table 2. Most important commercially available assays for HPV detection and/or 
genotyping. 
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8. Southern blot hybridization assays 
Southern blot hybridization was the first assay used to detect integrated HPV (Cooper et al., 
1991) and is generally used to classify new viral types (Lorincz, 1996). In Southern blot 
hybridization, the genome is extracted and the DNA chain is broken using restriction 
enzymes. The products are integrated into a gel and separated by electrophoresis. The 
fragments are denatured in situ, transferred to a nitrocellulose membrane, and hybridized 
with cloned HPV genomic probes. The probes are then labelled, often using radioisotopes. 
The detection of the labelled DNA hybrids is visualized by autoradiography. The sensitivity 
and the specificity of the assay are high, ranging between 70% and 80% the first and 90% the 
second (Caussy et al., 1988).There are no commercial kits available; the method is entirely 
laboratory-based, with existing reagents and methodologies. Despite high sensibility, 
specificity and application to cells and biopsies, Southern Blot is not suitable for routine 
application: it is time consuming, labourious, expensive and requires large amount of 
purifying DNA and radio labeled probes.  
9. Immunological techniques  
9.1 Enzyme-linked immunosorbent (ELISA) assays 
ELISA, also known as an enzyme immunoassay (EIA), is a technique used to detect the 
presence of antigens or antibodies in wide variety biological samples. The basic steps of this 
technique are the immobilization of the antigen and its detection by a labeled antibody. The 
immobilization can be accomplished by direct adsorption to the assay plate or indirectly via 
a capture antibody that has been already attached to the solid phase. The detection can be 
performed either directly by a labeled primary antibody or indirectly by a labeled secondary 
antibody. The labeled antibody reacts with a colourless substrate to produce a coloured 
product. The most widely used ELISA methods for detecting antigens is the Sandwich 
system (Figure 8) (Baker et al., 2009) . In this format, the antigen is sandwiched between two 
similar or different antibodies: a capture antibody, already bond to the solid phase, and an 
enzyme-conjugated secondary antibody.The enzyme reacted with the substrate producing a 
colour reaction which can be observed visually or measured with a spectrophotometer. The 
enzyme activity is directly proportional with the amount of the test antigen. Sandwich 
ELISA is especially used when the concentration of antigens is low or in presence of 
contaminating protein, as its sensitivity is 2-5 times more than other Elisa assays (Baker et 
al., 2009). The assay is very specific and simple (Biosupply, 2010, Chung et al., 2010) and 
there is no need to purify the antigen prior to use. On the other hand, only monoclonal 
antibodies can be used as matched pairs. They detect different epitopes on the antigen 
without impeding each other’s binding (Biosupply, 2010). 
To detect specific antibodies, the most widely used ELISA systems are the “indirect” and 
“competitive” systems (Figure 8). In the indirect system the antigen is directly adsorbed 
onto a solid phase and the primary and the conjugate antibodies are added to the plate 
successively. The intensity of the colour development between substrate-conjugate enzyme 
indicates the amount of antigen present. In the indirect ELISA there are many binding sites 
for the antibody, consequently more enzyme can be detected. A large variety of enzyme-
linked secondary antibodies are commercially available. The method is sensitive and 
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versatile.  The same enzyme-linked secondary antibody can detect many primary antibodies 
in one species. A non-specific signal might occur if cross-reactivity happens with the 
secondary antibody and an extra incubation step is required in the procedure. 
“Competitive” system is useful for identification and quantification of either antigen or 
antibody. The antigen is first incubated in presence of the unlabeled antibody, forming 
antigen-antibody complex, and after add to an antigen-coated plate. The production of 
colour elicited by antibody-antigen-substrate complex will be inversely proportional to the 
amount of antigen in the sample. In competitive ELISA, the secondary antibody competes 
with the sample antigen which is associated with the primary antibody. The more antigen in 
the sample the less labelled antibody is retained in the plate and the weaker the signal.  It is 
possible to use impure samples (Biomaterials, 2007)(Biomaterials, 2007)(Biomaterials, 
2007)(Biomaterials, 2007) and the assay is precise, rapid, accurate, and reproducible (Zhou et 
al., 2002). The use of  monoclonal antibodies is not so adequate because they are more 
difficult to find and cost more. The sensitivity and specificity are lower than the sandwich 
assay (Chung et al., 2010).   
 
Fig. 8. Schematic representation of Sandwich and competitive ELISA. 
The ELISA methodology is widely used to detect HPV antigens (Gutierrez-Xicotencatl et al., 
2009). Several works are focused on antibodies against the viral HPV16L1 capsid protein 
and the viral HPV16E6 and HPV16E7 oncoproteins.  L1 is the major capsid protein and it 
represents 80%-90% of the total viral proteins(Favre et al., 1975). The most of the antibody-
mediated immune responses are directed against L1 antigen (Carter et al., 2000, Rocha-
Zavaleta et al., 2003). A high frequency of anti-16L1 antibodies was found in patients with 
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high-risk HPV-associated LSIL and with cervical cancer. While a low antibody response was 
found from women without evidence of HPV infection and with low-risk HPV-associated 
LSIL (Cason et al., 1992, Ghosh et al., 1993, Di Lonardo et al., 1994, Rocha-Zavaleta et al., 
2004, Leon et al., 2009). Furthermore, it is possible to discriminate between high-risk HPV 
and low-risk HPV types by using the epitopes of the L1 capsid protein. The viral oncogenes 
E6 and E7 are associated with cancer; they modify the cell cycle in order to favour the viral 
genome replication and consequent late gene expression (Munger and Howley, 2002).  Most 
HPV-positive cancer cells maintain the expression of E6 and E7 (Baker et al., 1987, Shirasawa 
et al., 1987).  A higher HPV16E6 and HPV16E7 seropositivity was observed in patients with 
cervical cancer compared to healthy or with subjects displaying  early lesions (Kanda et al., 
1992, Ghosh et al., 1993, Viscidi et al., 1993, Di Lonardo et al., 1994, Dillner et al., 1994, Fujii 
et al., 1995, Fisher et al., 1996). Hence, E6 and E7 oncoproteins might be used to monitor 
infected woman at the very late stage of the infection.  
Several studies were focused on biomarker identification for early stages of cervical cancer 
in order to perform an early diagnosis of woman at risk of infection. For this reason the 
detection of viral HPV16E2, HPV16E4, and HPV16E5 proteins were studied. The expression 
of the HPVE4 protein is linked to cellular differentiation status (Breitburd et al., 1987, Chow 
et al., 1987a, Chow et al., 1987b, Doorbar et al., 1989, Palefsky et al., 1991) playing important 
role in the viral life cycle (Doorbar et al., 1986, Jareborg and Burnett, 1991). HPVE2 is the 
first protein to be expressed. High E2 levels repress expression of the E6 and E7 
oncoproteins. When the HPV genome is integrated in its host, E2 function are disrupted, 
preventing repression of E6/E7 (Munger and Howley, 2002). In relation to the expression of 
HPV16E2 and HPV16E4 there are conflicting opinions. Some authors found elevated 
responses for E2 antigen in patients with cervical cancer. Others reported anti-E2 antibodies 
in normal subjects and in women with CIN lesions (Dillner, 1990, Dillner et al., 1994, Veress 
et al., 1994, Marais et al., 1997). A higher E4 seropositivity was observed in pre-cancerous 
and cancerous lesions as well as in healthy individuals (Jochmus-Kudielka et al., 1989, Crum 
et al., 1990, Kochel et al., 1991, Snyder et al., 1991, Kanda et al., 1992, Dillner et al., 1994, 
Muller et al., 1995), while other studies found a  frequency of E4 antibodies in cancer 
patients higher than in normal subjects (Suchankova et al., 1991, Ghosh et al., 1993, 
Gaarenstroom et al., 1994). Moreover, an expression of the E4 protein was observed in 
patients with high-risk and low-risk HPV-associated but not in patients with cervical cancer 
(Crum et al., 1990, Vazquez-Corzo et al., 2003).  HPV16E5 is a weakly oncogenic protein 
which potentiates the transforming activity of E7(Bouvard et al., 1994, Valle and Banks, 
1995), but its biological activity is mostly unknown. Chang et. al (Chang et al., 2001) studied 
the HPV-16 E5 protein and found its expression in the lower third of the epithelium in LSIL. 
ELISA assays are quick, convenient, and very accurate. The method can achieve high 
sensitivities and specificities, favorably comparable with other radioimmunoassay (Moore et 
al., 1999, Leng et al., 2008). It can be performed in a small laboratory and it has the 
advantage of automation and multiplexing (Leng et al., 2008, Adler et al., 2009). Moreover, 
ELISA assays need small volume of blood and do not use radioisotopes or a costly radiation 
system. It is suitable for large numbers of specimens. False positive results might happen if 
the blocking solution is ineffective and the enzyme/substrate reaction is short term and 
needs a rapid reading. It is a time-consuming methodology ( >1.5h), uses refrigerated 
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reagents and probe design is difficult, but many kits are available.Considering PCR as a 
reference, ELISA methods are less sensitive than PCR (81.8%, 53%, 72.2% vs. 100%) but more 
specific (100%, 99%, 92.2% vs. 78%) for invasive cervical cancer (Meschede et al., 1998, Lack 
et al., 2005, Zaghloul, 2011) . 
9.2 Detection of HPV antibodies - western blot 
Western blot (alternatively, protein immunoblot) is an analytical technique used to identify 
proteins based on their ability to bind a specific antibody. The analysis can detect the target 
from a mixture of a great number of proteins from tissue homogenate or extract. It uses gel 
electrophoresis to separate native or denatured proteins by the length of the polypeptide or 
by the 3-D structure of the protein (Towbin et al., 1979). The proteins are transferred to a 
membrane made of nitrocellulose or polyvinylidene difluoride (PVDF) to make the proteins 
accessible to antibody detection (Khan et al., 2005). The membrane is "probed" for the 
protein of interest with a modified antibody which is linked to a reporter enzyme. When the 
enzyme is exposed to an appropriate substrate drives a colorimetric reaction (Renart et al., 
1979).  
Several works based on Western Blot technique have studied the high correlation between 
the oncogene proteins and cervical cancer (Jochmus-Kudielka et al., 1989, Kochel et al., 1991, 
Suchankova et al., 1991, Fujii et al., 1995) and the possible role of the protein E4 in cancer 
disease (Jochmus-Kudielka et al., 1989, Ghosh et al., 1993, Pedroza-Saavedra et al., 2000, 
Middleton et al., 2003) but  the results were controversial. The sensitivity of the Western blot 
assay is 67%. The specificity increases to 78%(Pedroza-Saavedra et al., 2000). 
There are kits based on detection of antigens using horseradish peroxidase (HRP) 
conjugated antibodies and the chemiluminescent substrate luminol. Chemiluminescent 
system detects the protein target using the light produced by the catalysis of an enzyme 
substrate. It is rapid and allows accurate identification of samples. With this assay it is 
possible to detect the target protein from a mixture of antigens (Molijn et al., 2005); it is,  
nevertheless, expensive, demanding and complex and it is impossible to analyze a large 
number of samples simultaneously (Molijn et al., 2005). 
10. Conclusions 
There are two major purposes for the use of molecular HPV diagnosis. The first is to identify 
women at cervical cancer risk; these can be detected through community-based screening 
programs or through clinical counseling. In this scenario, the use of a highly sensitive assay 
will overestimate some HPV infections that would be cleared by the immune system in less 
than 24 months (Moscicki, 2007). If a less sensitive or even a quantitative assay is chosen, the 
efficacy in identifying women at risk of progression might be more effective. The other 
purpose includes vaccination trials, epidemiological and natural history studies (Molijn et 
al., 2005). In this case, contrarily to the clinical application, a highly sensitive and 
reproducible assay is required, and it should include the broadest spectrum of HPV types. 
The ideal HPV testing for both goals should be a single assay with adjustable cut-off for 
detection, linked to a genotyping method (Molijn et al., 2005). Unfortunately, such method 
does not exist and combined detection systems have to be used. The molecular assays are 
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the gold standard for HPV testing and there are specific characteristics that positively 
distinguish each method. For instance, the extremely high sensitivity and specificity of PCR 
assays and the need of only small amounts of DNA template, makes it the support of several 
other high-quality assays. Within the signal amplification assays, hc2 is considered the most 
reliable assay and is a CE-IVD test. On the other hand, Southern blot technique is more 
expensive, requires large amount of purifying DNA and it is difficult to apply in routine 
practice due to time consumption; in situ hybridization is not as sensitive as the PCR and 
hc2 methods. The sampling and HPV DNA detection assays bearing different sensitivity 
and specificity, as shown above, are the most accountable aspects for the heterogeneity of 
the results. To overcome such problems, a combined detection system, to detect the presence 
of the HPV, and an antibody profile against different viral antigens, to stage the infection, 
will improve the signaling of persistent infections and prevent cervical cancer. 
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